EGFR and non-small cell lung carcinoma: The incidence of T790M among NSCLC patients who progressed upon EGFR-TKI as first-line therapy reported by other studies ranges from 36% to 70%, not largely differing between patients who have previously received a first- or second-generation EGFR-TKI [20,21,24,39,40,42,43].